Szilágyi J F, Pennington T H
J Virol. 1971 Aug;8(2):133-41. doi: 10.1128/JVI.8.2.133-141.1971.
A number of compounds related to rifampin which act as expected in the Escherichia coli system have been tested for their ability to inhibit the vaccinia particle deoxyribonucleic acid-dependent ribonucleic acid (RNA) polymerase in vitro. Some compounds are inactive even at concentrations of 500 mug/ml, others are able to produce partial inhibition, and others strongly inhibit the enzyme activity at 150 mug/ml or less. The inhibition, where present, operates immediately but appears to be at least partially reversible. At least one compound which is without effect against bacterial RNA polymerase is a potent inhibitor of the viral RNA polymerase. As the enzyme activity of rifampin-resistant mutants of vaccinia virus is inhibited to the same extent as that of the wild type, the observed in vitro effect on vaccinia virus RNA polymerase is not identical with the in vivo effect specifically directed against a vaccinia-specified protein.
一些与利福平相关的化合物在大肠杆菌系统中表现出预期的作用，已对它们在体外抑制牛痘病毒颗粒脱氧核糖核酸依赖性核糖核酸（RNA）聚合酶的能力进行了测试。一些化合物即使在浓度为500微克/毫升时也无活性，其他化合物能够产生部分抑制作用，还有一些化合物在150微克/毫升或更低浓度时能强烈抑制酶活性。若存在抑制作用，其作用立即显现，但似乎至少部分是可逆的。至少有一种对细菌RNA聚合酶无作用的化合物是病毒RNA聚合酶的有效抑制剂。由于牛痘病毒利福平抗性突变体的酶活性与野生型受到相同程度的抑制，所以观察到的对牛痘病毒RNA聚合酶的体外作用与针对牛痘病毒特定蛋白的体内作用并不相同。
